Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
Sean WassermanRosleine Antilus-SainteNoha AbdelgawadNarineh M OdjourianMelissa CristaldoMaureen DougherFirat KayaMatthew ZimmermanPaolo DentiMartin GengenbacherPublished in: Antimicrobial agents and chemotherapy (2024)
Tuberculous meningitis (TBM) has a high mortality, possibly due to suboptimal therapy. Drug exposure data of antituberculosis agents in the central nervous system (CNS) are required to develop more effective regimens. Rifabutin is a rifamycin equivalently potent to rifampin in human pulmonary tuberculosis. Here, we show that human-equivalent doses of rifabutin achieved potentially therapeutic exposure in relevant CNS tissues in a rabbit model of TBM, supporting further evaluation in clinical trials.
Keyphrases
- pulmonary tuberculosis
- cerebrospinal fluid
- endothelial cells
- clinical trial
- induced pluripotent stem cells
- pluripotent stem cells
- gene expression
- mycobacterium tuberculosis
- emergency department
- type diabetes
- electronic health record
- risk factors
- bone marrow
- mesenchymal stem cells
- cardiovascular disease
- coronary artery disease
- open label
- study protocol
- adverse drug
- artificial intelligence
- phase iii